Role of p38 MAPK activation in AIDS pathogenesis
p38 MAPK 激活在 AIDS 发病机制中的作用
基本信息
- 批准号:9235219
- 负责人:
- 金额:$ 86.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-03-01 至 2020-02-29
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAdverse effectsAffectAnimalsAntibodiesAntigen-Presenting CellsBiological PreservationBrainCCR5 geneCD4 Positive T LymphocytesCD8-Positive T-LymphocytesCause of DeathCell LineageCellsCercocebus atysCercopithecus pygerythrusClinical TrialsConfocal MicroscopyDataDendritic CellsDiseaseDisease ProgressionDrug KineticsEvaluationFlow CytometryGene ActivationGene ExpressionGene Expression ProfilingGene TargetingGenesGoalsHIVHIV InfectionsHIV-1HumanImage AnalysisImmune responseImmunizationImmunohistochemistryIn VitroIndividualInfectionInflammationInflammatoryIntegraseInterferonsInterruptionInterventionIntestinesInvestigationLightLinkMAP Kinase GeneMAPK14 geneMacacaMaintenanceMapsMeasuresMediatingMethodsMitogen-Activated Protein Kinase InhibitorMolecular ProfilingMononuclearMucous MembraneOralPathogenesisPathologyPathway interactionsPeptide HydrolasesPeripheral Blood Mononuclear CellPharmaceutical PreparationsPharmacotherapyPlasmaPlayPopulationPrimatesProductionProteinsRegimenReportingResistanceRoleSIVSafetySamplingSerumSignal PathwayStaining methodStainsSuperantigensSurfaceSurrogate MarkersT-LymphocyteTestingTissuesTranscriptional ActivationViral AntigensViral Load resultViral reservoirViremiaVirusVirus DiseasesWorkantiretroviral therapychemokinecytokineexperimental studygene producthuman diseaseimmune activationin vivoinhibitor/antagonistinterestlymph nodesmacrophagememory CD4 T lymphocytemicroscopic imagingmonocytenervous system disordernonhuman primatepublic health relevancequantitative imagingrectaltranscription factortreatment effectvirtual
项目摘要
DESCRIPTION (provided by applicant): Differences in immune activation have been identified as the single most significant difference between AIDS- susceptible and resistant species. Immune activation can be induced by a variety of mechanisms, including stimulation of immune responses by viral antigens, production of a superantigen, and/or production of activating cytokines and chemokines. It is quite likely that more than one mechanism is occurring simultaneously during HIV infection. We have shown that HIV and SIV infections modulates primate APC and T-cell gene expression and that at least a subset of the IFN-stimulated genes (ISG), reprogrammed in infected human and RM iDC, are not affected by SIV infection in APC of AIDS resistant species. We postulated that induction and maintenance of immune activation could depend on the induction by HIV or SIV of cell pathways leading to the production of immunoactivating cytokines and chemokines and have shown that this is the case in vitro. p38 MAPK, which has been reported to be activated in HIV and SIV infection, is key in the pathway of induction of ISG and is associated in vivo with the some of the pathology produced by HIV and SIV infection in AIDS susceptible primates. As inhibitors of p38 MAPK are available and currently tested in human trials for other diseases, we intend to evaluate the effects of treating SIV-infected macaques with a p38 inhibitor that has been shown to reduce immune activation in trials for different human diseases in conjunction with ART. Our goals are: 1 to evaluate in vivo the impact that PH-797804 alone or added to ART has on immune activation in SIV- infected RM. As primary end points we will evaluate expression of surface and intracellular molecules linked to immune activation and gene expression profiles in RM PBMC, lymph node and rectal mononuclear cell (MNC) subpopulations, and plasma levels of inflammatory cytokines and chemokines; 2. to evaluate the effects that treatments have on viral loads, viral reservoirs, and preservation of central memory CD4+ T cells as secondary end points; 3. to evaluate the treatment impact on protein levels of selected IGS and on immune activation markers in lymph node, intestinal tissue and brain sections.
描述(由申请人提供):免疫激活的差异已被确定为艾滋病易感物种和抗性物种之间最显著的差异。免疫活化可以通过多种机制诱导,包括通过病毒抗原刺激免疫应答、产生超抗原和/或产生活化细胞因子和趋化因子。在HIV感染过程中,很可能有一种以上的机制同时发生。我们已经证明,HIV和SIV感染调节灵长类动物APC和T细胞基因表达,并且在感染的人和RM iDC中重新编程的至少一个IFN刺激基因(ISG)子集不受SIV感染的影响艾滋病抗性物种的APC。我们假设免疫激活的诱导和维持可能依赖于HIV或SIV对导致免疫激活细胞因子和趋化因子产生的细胞途径的诱导,并且已经表明这是体外的情况。已报道在HIV和SIV感染中被激活的p38 MAPK是诱导ISG的途径中的关键,并且在体内与由HIV和SIV感染在AIDS易感灵长类动物中产生的一些病理学相关。由于p38 MAPK的抑制剂是可用的,并且目前在其他疾病的人体试验中进行了测试,我们打算评估用p38抑制剂治疗SIV感染的猕猴的效果,该抑制剂已被证明在与ART结合的不同人类疾病的试验中减少免疫激活。我们的目标是:1以在体内评价PH-797804单独或添加到ART中对SIV感染的RM中的免疫活化的影响。作为主要终点,我们将评估与RM PBMC、淋巴结和直肠单核细胞(MNC)亚群中的免疫活化和基因表达谱相关的表面和细胞内分子的表达,以及炎性细胞因子和趋化因子的血浆水平;评估治疗对病毒载量、病毒储库和中央记忆CD 4 + T细胞的保存的影响作为次要终点; 3.评价给药对选定IGS蛋白水平以及对淋巴结、肠组织和脑切片中免疫活化标志物的影响。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNA ALDOVINI其他文献
ANNA ALDOVINI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNA ALDOVINI', 18)}}的其他基金
Prophylactic oral vaccination for SIV and SHIV infections and AIDS prevention
针对 SIV 和 SHIV 感染以及艾滋病预防的预防性口服疫苗接种
- 批准号:
9322435 - 财政年份:2016
- 资助金额:
$ 86.07万 - 项目类别:
Role of p38 MAPK activation in AIDS pathogenesis
p38 MAPK 激活在 AIDS 发病机制中的作用
- 批准号:
8811918 - 财政年份:2014
- 资助金额:
$ 86.07万 - 项目类别:
Role of p38 MAPK activation in AIDS pathogenesis
p38 MAPK 激活在 AIDS 发病机制中的作用
- 批准号:
8731523 - 财政年份:2014
- 资助金额:
$ 86.07万 - 项目类别:
In vivo suppression of SIV-mediated immune activation
体内抑制 SIV 介导的免疫激活
- 批准号:
8603383 - 财政年份:2013
- 资助金额:
$ 86.07万 - 项目类别:
In vivo suppression of SIV-mediated immune activation
体内抑制 SIV 介导的免疫激活
- 批准号:
8717584 - 财政年份:2013
- 资助金额:
$ 86.07万 - 项目类别:
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection
HIV 神经变性和富马酸二甲酯 (DMF/MMF) 神经保护的途径
- 批准号:
8472538 - 财政年份:2011
- 资助金额:
$ 86.07万 - 项目类别:
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection
HIV 神经变性和富马酸二甲酯 (DMF/MMF) 神经保护的途径
- 批准号:
8669822 - 财政年份:2011
- 资助金额:
$ 86.07万 - 项目类别:
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection
HIV 神经变性和富马酸二甲酯 (DMF/MMF) 神经保护的途径
- 批准号:
8368087 - 财政年份:2011
- 资助金额:
$ 86.07万 - 项目类别:
Pathways of HIV neurodegeneration and dimethyl fumarate (DMF/MMF) neuroprotection
HIV 神经变性和富马酸二甲酯 (DMF/MMF) 神经保护的途径
- 批准号:
8210631 - 财政年份:2011
- 资助金额:
$ 86.07万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 86.07万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 86.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 86.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 86.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 86.07万 - 项目类别:
Studentship